• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Revisiting thiopurines and therapeutic drug monitoring in IBD: Insights and implications in the Indian context.

作者信息

Singh Arshdeep, Sood Ajit

机构信息

Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, 141 001, India.

出版信息

Indian J Gastroenterol. 2025 Aug 29. doi: 10.1007/s12664-025-01864-7.

DOI:10.1007/s12664-025-01864-7
PMID:40879708
Abstract
摘要

相似文献

1
Revisiting thiopurines and therapeutic drug monitoring in IBD: Insights and implications in the Indian context.重新审视硫唑嘌呤及炎症性肠病的治疗药物监测：印度背景下的见解与启示
Indian J Gastroenterol. 2025 Aug 29. doi: 10.1007/s12664-025-01864-7.
2
Klebsiella pneumoniae contributes to altered cytotoxicity of thiopurines in vitro: Possible implications of biotransformation and bacterial metabolism.肺炎克雷伯菌导致硫嘌呤类药物在体外细胞毒性改变：生物转化和细菌代谢的潜在影响
Br J Pharmacol. 2025 Sep;182(18):4281-4298. doi: 10.1111/bph.70089. Epub 2025 May 29.
3
Therapeutic Drug Monitoring and Pharmacogenomics of Thiopurines in Inflammatory Bowel Disease: International Guidelines Revisited.炎症性肠病中硫嘌呤类药物的治疗药物监测与药物基因组学：重新审视国际指南
Ther Drug Monit. 2025 Aug 29. doi: 10.1097/FTD.0000000000001373.
4
and genotyping, TPMT enzyme activity and metabolite determination for thiopurines therapy: a reference laboratory experience.硫嘌呤类药物治疗的基因分型、TPMT酶活性及代谢物测定：参考实验室经验
Pharmacogenomics. 2024;25(16-18):679-688. doi: 10.1080/14622416.2025.2463866. Epub 2025 Feb 16.
5
Clinical utility of thiopurine metabolite levels in monitoring patients with inflammatory bowel disease: A single-centre retrospective study.硫嘌呤代谢物水平在炎症性肠病患者监测中的临床应用：一项单中心回顾性研究。
Indian J Gastroenterol. 2025 Jul 19. doi: 10.1007/s12664-025-01831-2.
6
Cross-ethnic evaluation of gut microbial signatures reveal increased colonization with oral pathobionts in the north Indian inflammatory bowel disease cohort.肠道微生物特征的跨种族评估显示，北印度炎症性肠病队列中口腔致病共生菌的定植增加。
Intest Res. 2025 Jul 14. doi: 10.5217/ir.2024.00216.
7
A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.炎症性肠病患者发生肝脾 T 细胞淋巴瘤的相关因素的系统评价。
Clin Gastroenterol Hepatol. 2011 Jan;9(1):36-41.e1. doi: 10.1016/j.cgh.2010.09.016. Epub 2010 Oct 1.
8
Thiopurines and Intrahepatic Cholestasis of Pregnancy in Systemic Lupus Erythematosus and Inflammatory Bowel Disease Pregnancies.硫嘌呤与系统性红斑狼疮及炎症性肠病妊娠中的妊娠期肝内胆汁淤积症
Am J Gastroenterol. 2025 Jul 23. doi: 10.14309/ajg.0000000000003652.
9
Reframing Recovery: Revisiting Mental Health Recovery Narratives Framework Through Indian Memoirs.重塑康复：通过印度回忆录重新审视心理健康康复叙事框架
J Eval Clin Pract. 2025 Aug;31(5):e70229. doi: 10.1111/jep.70229.
10
Examination of the TPMT and NUDT15*3 Variants to Predict the Response to Thiopurines in an Italian Cohort of Patients with Inflammatory Bowel Disease.检测TPMT和NUDT15*3变体以预测意大利炎症性肠病患者队列对硫嘌呤类药物的反应。
Int J Mol Sci. 2025 Aug 14;26(16):7860. doi: 10.3390/ijms26167860.

本文引用的文献

1
Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy.创新硫嘌呤治疗药物监测：以 DNA-硫鸟嘌呤核苷酸 (DNA-TG) 为包容性生物标志物的硫嘌呤治疗的系统评价和荟萃分析。
Clin Pharmacokinet. 2024 Aug;63(8):1089-1109. doi: 10.1007/s40262-024-01393-0. Epub 2024 Jul 20.
2
Low risk of malignancies with thiopurines in an Indian cohort of patients with Inflammatory bowel disease.印度炎症性肠病患者队列中使用硫唑嘌呤发生恶性肿瘤的风险较低。
Indian J Gastroenterol. 2025 Jun;44(3):390-391. doi: 10.1007/s12664-024-01615-0.
3
Uphill battle: Innovation of thiopurine therapy in global inflammatory bowel disease care.
uphill battle：硫唑嘌呤治疗在全球炎症性肠病治疗中的创新。
Indian J Gastroenterol. 2024 Feb;43(1):36-47. doi: 10.1007/s12664-024-01529-x. Epub 2024 Feb 21.
4
Therapeutic drug monitoring in inflammatory bowel disease: A practical approach.炎症性肠病的治疗药物监测：一种实用方法。
Indian J Gastroenterol. 2024 Feb;43(1):93-102. doi: 10.1007/s12664-024-01527-z. Epub 2024 Feb 8.
5
The Role of Pharmacogenetics in the Therapeutic Response to Thiopurines in the Treatment of Inflammatory Bowel Disease: A Systematic Review.药物遗传学在炎症性肠病治疗中硫嘌呤类药物治疗反应中的作用：一项系统评价
J Clin Med. 2023 Oct 25;12(21):6742. doi: 10.3390/jcm12216742.
6
Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis.硫嘌呤类药物在炎症性肠病患者中具有长期疗效，与起始时的疾病持续时间无关：一项倾向评分匹配分析。
J Crohns Colitis. 2024 Feb 26;18(2):192-203. doi: 10.1093/ecco-jcc/jjad135.
7
A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients.Rac1/pSTAT3 蛋白水平在 T 淋巴细胞中评估巯嘌呤治疗炎症性肠病患者药效学效应的潜力报告。
Sci Rep. 2022 Sep 22;12(1):15806. doi: 10.1038/s41598-022-20197-5.
8
Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India.尽管在印度北部进行了纵向队列分析，但炎症性肠病患者长期使用硫嘌呤类药物，患淋巴瘤和非黑素瘤皮肤癌的风险仍然较低。
J Gastroenterol Hepatol. 2022 Aug;37(8):1544-1553. doi: 10.1111/jgh.15880. Epub 2022 May 10.
9
Use of thiopurines in inflammatory bowel disease: an update.硫唑嘌呤在炎症性肠病中的应用：最新进展
Intest Res. 2022 Jan;20(1):11-30. doi: 10.5217/ir.2020.00155. Epub 2021 Apr 15.
10
Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study.硫唑嘌呤和5-氨基水杨酸维持英夫利昔单抗诱导的急性重症激素难治性溃疡性结肠炎临床缓解的成本较低且疗效高（MIRACLE）：一项多中心研究
Intest Res. 2022 Jan;20(1):64-71. doi: 10.5217/ir.2020.00100. Epub 2021 Feb 3.